Syndax Pharmaceuticals (SNDX) Total Non-Current Liabilities (2015 - 2026)

Syndax Pharmaceuticals' Total Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $344.9 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 4.16% year-over-year to $344.9 million in Q1 2026; TTM through Mar 2026 was $344.9 million, a 4.16% increase from a year earlier, with the FY2025 full-year figure at $345.0 million, up 3.55% from the prior year.
• Total Non-Current Liabilities was little changed at $344.9 million in Q1 2026 per SNDX's latest filing, from $345.0 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $345.0 million in Q4 2025 and bottomed at $2000.0 in Q3 2024.
• The 5-year median for Total Non-Current Liabilities is $1.1 million (2023), against an average of $119.9 million.
• Across the five-year window, Total Non-Current Liabilities sank 99.77% in 2024 and jumped 16108650.0% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $722000.0 in 2022, then slipped by 18.56% to $588000.0 in 2023, then jumped by 56556.97% to $333.1 million in 2024, then advanced by 3.55% to $345.0 million in 2025, then slipped by 0.03% to $344.9 million in 2026.
• Per Business Quant, the three latest SNDX Total Non-Current Liabilities figures stand at $344.9 million (Q1 2026), $345.0 million (Q4 2025), and $322.2 million (Q3 2025).